Serbia and Pakistan have agreed to participate in the Phase 3 trials of CNBG's vaccine candidates while Sinovac has received approval from Turkey and Bangladesh. Serbia will test two vaccines developed by CNBG's Wuhan and Beijing units, and Pakistan will test the Beijing unit's candidate, the company told Reuters. CNBG's Phase 3 trials are expected to involve 50,000 people in about 10 countries, said CNBG vice president Zhang Yuntao. Zhang said foreign countries have expressed interest in ordering a combined 500 million doses of its vaccines. The company will soon begin providing its vaccines to Chinese staffers working in overseas embassies and consulates, he added.

Source: bd News24 September 06, 2020 03:33 UTC